FirstDerm

Market position

First Derm operates in the consumer teledermatology segment, positioning its service as a lower-cost, faster alternative to waiting for an in-person dermatology appointment. The company states its users see a dermatologist two weeks faster than the US average wait of 32 days. Third-party listings classify it as a pre-seed-stage health technology company with 1-10 employees, and it has been included in a roundup of Barcelona healthtech startups.

First Derm markets itself as a fully anonymous online dermatology platform requiring no account creation or personally identifiable information, and emphasises that every case is read by a human board-certified dermatologist rather than an AI or machine-learning tool. Other stated points of difference are user-selected response-time tiers with transparent one-off pricing, HIPAA compliance, and availability without appointments across many countries and languages.

Technology

The platform consists of a web submission form and native iOS and Android applications through which users upload two photos (one close-up, one overview) plus a symptom and history questionnaire. Cases are tracked by a unique eight-digit case number, stored on the company's servers for ten years, and results are delivered via push notification or email and viewable through a "View Case" page that can be exported as a PDF. The company describes the service as HIPAA-compliant and secure, with data encrypted in transit and no data shared with third parties per its app store disclosure. Reviews are performed by human dermatologists; de-identified case material may be used for machine learning to improve the service. The company has also developed a dermatoscope accessory, HÜD, for mole scanning.

Go-to-market

Distribution is direct-to-consumer through the firstderm.com web form and the First Derm mobile apps on the Apple App Store and Google Play, supported by a dermatology content blog covering skin conditions and seasonal skin topics. The company publishes user testimonials sourced from app stores and its feedback database, cites peer-reviewed research supporting its outcomes, and has used press coverage and a crowdfunding campaign for hardware to build visibility.

Consumers worldwide with skin, hair, nail or STI-related concerns, including adults, teens and children, who want a fast professional opinion without an in-person appointment. Recurring user profiles cited include people facing long dermatology wait times, those without insurance or seeking to avoid consultation costs, travellers, parents, and people with sensitive or intimate concerns who prefer anonymity.

Geography

The company is listed in Berkeley, California, with the app developer address for iDoc24, Inc. given as 1355 Market St Ste 488, San Francisco, CA 94103. The service originated in Sweden and the underlying iDoc24 app was initially available only in Europe. Pricing is published for both the United States (USD) and Europe (EUR), with a GBP price also quoted, and app store materials state the service reaches over 160 countries in seven languages. The company has also appeared in coverage of the Barcelona healthtech startup ecosystem.

History

The service began in Sweden in 2009 as an STD triage app and was later broadened into a general teledermatology platform. Operating entity iDoc24's original Europe-only app carried the iDoc24 name; in 2014 the platform's focus was expanded to include children's skin problems, and the First Derm consumer brand drew press coverage in US technology and health-industry media during 2014. In 2015 the company added a dermatoscope to its offering and ran an Indiegogo crowdfunding campaign for a "smart mole scanner" named HÜD, at which point it described itself as bootstrapped with no institutional funding. Company materials date the current service as operational since 2014. Third-party listings record a founding year of 2012 and a pre-seed stage.

Risks & controversies

The company states that its output is informational and does not constitute a diagnosis, treatment plan or physician-patient relationship, and that it does not write prescriptions, directing users with conditions requiring tests, biopsies, advanced procedures, urgent care or long-term monitoring to in-person providers. Diagnostic certainty is described as lower when submitted images are blurry or poorly focused. The anonymous model means the company does not disclose contact details for users or reviewing doctors, and de-identified case data may be reused for research and machine learning.